Literature DB >> 23238803

A feasibility study for determining ablative margin with 3D-CEUS-CT/MR image fusion after radiofrequency ablation of hepatocellular carcinoma.

S Zhong-Zhen, L Kai, Z Rong-Qin, X Er-Jiao, Z Ting, Z Ao-Hua, Y Shu-Fang, H Xu-Qi.   

Abstract

PURPOSE: To explore the feasibility and value of 3D-CEUS-CT/MR image fusion in evaluating ablative margin (AM) after radiofrequency ablation of hepatocellular carcinoma. METHODS AND MATERIALS: There were 49 HCC in 41 patients enrolled in our prospective study. The AM were evaluated with 3D-CEUS-CT/MR image fusion, the results were divided into two groups: in group A, the tumor was completely ablated with a 5 mm AM; in group B, the tumor was completely ablated, but a 5 mm AM was not obtained. The time used in US-CT/MR image fusion and 3 D image post-processing, the technical success rate of 3D-CEUS-CT/MR image fusion and the relation between LTP and AM were observed.
RESULTS: The time taken for US-CT/MR image fusion and 3 D image post-processing was 9.2 ± 2.1 min (6 - 12 min), 14.6 ± 2.6 min (9 - 20 min), respectively. The technical success rate of 3D-CEUS-CT/MR image fusion was 81.6 % (40/49). 27 HCC had sufficient AM (group A) and 13 HCC had insufficient AM (group B). The LTP rates in groups A and B were 0/27 and 4/13, respectively. There was a significant difference between groups A and B (P = 0.002). There was a significant negative correlation between LTP and AM (r = -1.000, P< 0.001), and the locations of LTP and insufficient AM were concordant.
CONCLUSIONS: The results suggest that 3D-CEUS-CT/MR image fusion is feasible and useful in evaluating the AM after HCC ablation. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23238803     DOI: 10.1055/s-0032-1325466

Source DB:  PubMed          Journal:  Ultraschall Med        ISSN: 0172-4614            Impact factor:   6.548


  8 in total

Review 1.  [Possibilities of sonographic image fusion: Current developments].

Authors:  E M Jung; D-A Clevert
Journal:  Radiologe       Date:  2015-11       Impact factor: 0.635

2.  A measure to assess the ablative margin using 3D-CT image fusion after radiofrequency ablation of hepatocellular carcinoma.

Authors:  Hui Tang; Yunqiang Tang; Jian Hong; Tiejun Chen; Cong Mai; Peng Jiang
Journal:  HPB (Oxford)       Date:  2014-10-24       Impact factor: 3.647

3.  Assessment of radiofrequency ablation margin by MRI-MRI image fusion in hepatocellular carcinoma.

Authors:  Xiao-Li Wang; Kai Li; Zhong-Zhen Su; Ze-Ping Huang; Ping Wang; Rong-Qin Zheng
Journal:  World J Gastroenterol       Date:  2015-05-07       Impact factor: 5.742

Review 4.  [Contrast-enhanced ultrasound (CEUS) and image fusion for procedures of liver interventions].

Authors:  E M Jung; D A Clevert
Journal:  Radiologe       Date:  2018-06       Impact factor: 0.635

5.  Evaluation of the ablation margin of hepatocellular carcinoma using CEUS-CT/MR image fusion in a phantom model and in patients.

Authors:  Kai Li; Zhongzhen Su; Erjiao Xu; Qiannan Huang; Qingjing Zeng; Rongqin Zheng
Journal:  BMC Cancer       Date:  2017-01-19       Impact factor: 4.430

6.  Improving Ablation Safety for Hepatocellular Carcinoma Proximal to the Hilar Bile Ducts by Ultrasound-MR Fusion Imaging: A Preliminary Comparative Study.

Authors:  Yujia You; Yinglin Long; Ronghua Yan; Liping Luo; Man Zhang; Lu Li; Qingjing Zeng; Kai Li; Rongqin Zheng; Erjiao Xu
Journal:  Front Oncol       Date:  2021-03-01       Impact factor: 6.244

7.  Feasibility and Efficacy of Fusion Imaging Systems for Immediate Post Ablation Assessment of Liver Neoplasms: Protocol for a Rapid Systematic Review.

Authors:  Pragati Rai; Sarada Dakua; Julien Abinahed; Shidin Balakrishnan
Journal:  Int J Surg Protoc       Date:  2021-09-17

8.  Improvement of ablative margins by the intraoperative use of CEUS-CT/MR image fusion in hepatocellular carcinoma.

Authors:  Kai Li; Zhong-Zhen Su; Er-Jiao Xu; Jin-Xiu Ju; Xiao-Chun Meng; Rong-Qin Zheng
Journal:  BMC Cancer       Date:  2016-04-18       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.